Abstract
The noninvasive detection of apoptosis, or programmed cell death, is an important biomarker for the severity/progression of diseases and the efficacy of anticancer therapies. In the past decade a rapid expansion in the number of apoptosis imaging agents and techniques offers an increasingly wide selection of approaches for the assessment of apoptosis in vivo. The goal of this review is to provide a general account of existing and emerging apoptosis imaging techniques based on their modes of actions; and to critically discuss the major advantages and obstacles facing the field of apoptosis imaging. In conclusion, tremendous progress has been made in applying the concept of apoptosis imaging toward diagnostic needs. However, for imaging strategies involving exogenous agents, we must recognize the intrinsic distinction between probe density and target density, and appreciate the complexity of apoptosis imaging within the context of probe behaviors in the target tissue. For non-pharmaceutical imaging strategies, there is a continued drive to improve the specificity and applicability of these endogenous markers. Overall, what remains to be addressed, and is critical to clinical translation, is the noninvasive quantification, in addition to detection, of apoptosis in vivo.
Anti-Cancer Agents in Medicinal Chemistry
Title: In Vivo Apoptosis Imaging Agents and Strategies
Volume: 9 Issue: 9
Author(s): Ming Zhao
Affiliation:
Keywords: Apoptosis, imaging, probe
Abstract: The noninvasive detection of apoptosis, or programmed cell death, is an important biomarker for the severity/progression of diseases and the efficacy of anticancer therapies. In the past decade a rapid expansion in the number of apoptosis imaging agents and techniques offers an increasingly wide selection of approaches for the assessment of apoptosis in vivo. The goal of this review is to provide a general account of existing and emerging apoptosis imaging techniques based on their modes of actions; and to critically discuss the major advantages and obstacles facing the field of apoptosis imaging. In conclusion, tremendous progress has been made in applying the concept of apoptosis imaging toward diagnostic needs. However, for imaging strategies involving exogenous agents, we must recognize the intrinsic distinction between probe density and target density, and appreciate the complexity of apoptosis imaging within the context of probe behaviors in the target tissue. For non-pharmaceutical imaging strategies, there is a continued drive to improve the specificity and applicability of these endogenous markers. Overall, what remains to be addressed, and is critical to clinical translation, is the noninvasive quantification, in addition to detection, of apoptosis in vivo.
Export Options
About this article
Cite this article as:
Zhao Ming, In Vivo Apoptosis Imaging Agents and Strategies, Anti-Cancer Agents in Medicinal Chemistry 2009; 9 (9) . https://dx.doi.org/10.2174/187152009789377691
DOI https://dx.doi.org/10.2174/187152009789377691 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
5-Benzylidene-3,4-dihalo-furan-2-one derivatives inhibit human leukemia cancer cells through suppression of NF-κB and GSK-3β
Anti-Cancer Agents in Medicinal Chemistry Can microRNAs be Biomarkers or Targets for Therapy of Ischemic Coronary Artery Disease in Metabolic Syndrome?
Current Drug Targets Evidence-Based Percutaneous Closure of the Left Atrial Appendage in Patients with Atrial Fibrillation
Current Cardiology Reviews Adipose-Derived Stromal/Stem Cells (ASC) in Regenerative Medicine: Pharmaceutical Applications
Current Pharmaceutical Design Cell Therapy for Myocardial Regeneration
Current Molecular Medicine Curcumin Reverts the Protein Differential Expression in the Liver of the Diabetic Obese db/db Mice
Current Proteomics Remote Ischemic Conditioning Improves Cognitive Function During Cerebral Vascular Injury Through the Induction of Autophagy
Current Neurovascular Research Cardiovascular Disease in the Systemic Vasculitides
Current Vascular Pharmacology The Right Ventricle: Biologic Insights and Response to Disease
Current Cardiology Reviews Modulatory Role of Nitric Oxide/cGMP System in Endothelin-1-Induced Signaling Responses in Vascular Smooth Muscle Cells
Current Cardiology Reviews Role of Nuclear Steroid Receptors in Apoptosis
Current Medicinal Chemistry Differential Effects of Trans and Polyunsaturated Fatty Acids on Ischemia/ Reperfusion Injury and its Associated Cardiovascular Disease States
Current Pharmaceutical Design High Density Lipoprotein Administration: A New Therapeutic Modality for the Treatment of Cardiovascular Diseases
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Formaldehyde as a trigger for protein aggregation and potential target for mitigation of age-related, progressive cognitive impairment
Current Topics in Medicinal Chemistry Is Glyburide Safe in Pregnancy?
Current Pharmaceutical Biotechnology Ca2+ Signalling in Damaged Endothelium and Arterial Remodelling: Do Connexin Hemichannels Provide a Suitable Target to Prevent In-stent Restenosis?
Current Drug Therapy PUFA for Human Health: Diet or Supplementation?
Current Pharmaceutical Design Atrial Fibrillation and Hypertension: “Quo Vadis”
Current Hypertension Reviews Role of miRNAs in Muscle Stem Cell Biology: Proliferation, Differentiation and Death
Current Pharmaceutical Design Pharmacological Adjuvant Therapies in Primary Coronary Interventions: Bivalirudin
Cardiovascular & Hematological Agents in Medicinal Chemistry